Research Article
Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa
Table 1
Demographic and clinical characteristics of patients with P. aeruginosa related nosocomial infection.
| Characteristics | Number of patients (%) (: 120) |
| Age; years (mean ± SD) | 58.4 ± 19.2 | >60 years old | 70–58.3 | Male/female | 62–50.8/58–49.2 | Intensive care unit (ICU) | | NR-ICU | 34–28.3 | AR-ICU | 56–46.6 | NRS-ICU | 34–28.3 | Stay at ICU (mean ± SD) | 112.7 ± 87.8 | Intensive care unit stay > 60 days | 82–68.3 | Polymicrobial infection | 90–75 | Multiple isolation of P. aeruginosa | 50–41.7 | Time at risk (mean ± SD) | 55.4 ± 52.4 | APACHE II score (mean ± SD) (at time of isolation) | 23.6 ± 4.14 | Invasive procedures and comorbid disease | | Mechanic ventilation | 96–80 | Enteral nutrition | 105–87.5 | Total parenteral nutrition | 87–72.5 | Thoracotomy tube | 17–14.2 | Urinary catheterization | 119–99.2 | Central venous catheterization | 108–90 | History of cerebrovascular disease | 78–65 | History of cardiovascular disease | 98–81.7 | History of surgical operation | 40–33.3 | History of chronic renal disease | 32–26.7 | History of malignancy | 69–57.5 | Prior antibiotic use | | Carbapenems | 73–60.8 | Meropenem | 67–90.1 | Piperacillin-tazobactam | 50–41.7 | Amikacin | 44–36.7 | Teicoplanin | 38–31.7 | Cefazolin | 29–24.2 | Ceftriaxone | 22–18.3 | Ciprofloxacin | 10–8.3 | Ceftazidime | 9–7.5 |
|
|
NR-ICU: neurology intensive care unit, AR-ICU: anesthesia-reanimation intensive care unit, and NRS-ICU: neurosurgery intensive care unit.
|